[ad_1]
According to them, the vaccine in children would be administered in a lower dose than in people 12 years and older.
„[Tyrimo] The vaccine was safe, well tolerated and showed a strong neutralizing antibody response in participants aged five to 11 years, “US pharmaceutical giant Pfizer and its German partner BioNTech said in a joint statement.
They said they planned to send their data to regulators in the European Union, the United States and around the world “as soon as possible.”
These are the first results of the test in children under 12 years of age. Moderna’s trials in the 6-11 age group are still ongoing.
Both the Pfizer-BioNTech and Moderna vaccines are already used in children 12 years of age and older and around the world.
Although children are at lower risk of developing severe coronavirus, there is concern that a highly contagious delta variant could lead to more severe cases.
Vaccination of children is also considered essential to keep schools open. It should also help end the pandemic.
“Our goal is to provide the protection provided by the vaccine [ir] for these younger residents, ”said Albert Bourla, CEO of Pfizer. He noted that since July, COVID-19 cases in children have “increased by approximately 240 percent” in the United States.
In the experimental age group 5 to 11 years, children received two doses of 10 micrograms each; the second was injected 21 days after the first, the companies said. 30 microgram doses are used in the elderly.
The 10-microgram dose was “carefully chosen … for safety, tolerability and immunogenicity” in that age group, according to the report.
By the end of the year, children under the age of five.
The side effects were “generally comparable to those in participants aged 16 to 25,” he said.
The most common complaints were pain and swelling at the injection site, headache, chills, and fever.
Israel has already specifically authorized lower doses of Pfizer to vaccinate children ages 5 to 11 who are considered to be at significant risk of developing COVID-19 or dying from the disease.
Pfizer and BioNTech are also testing their vaccine for children ages six months to two years, as well as children ages two to five.
The results of these tests are expected in the fourth quarter of this year, the companies said.
In total, up to 4.5 thousand people participate in the Pfizer and BioNTech trials in the United States, Finland, Poland and Spain. children from six months to 11 years.
Like the competitor Moderna, the Pfizer-BioNTech vaccine was developed using a new information RNA technology that carries genetic instructions to cells to produce a coronavirus “needle” protein to trigger an antibody response immediately when the body is released. encounters a real virus.
[ad_2]
